Metropolis Healthcare Ltd
NSE:METROPOLIS

Watchlist Manager
Metropolis Healthcare Ltd Logo
Metropolis Healthcare Ltd
NSE:METROPOLIS
Watchlist
Price: 1 921.8 INR 0.07% Market Closed
Market Cap: 99.6B INR

Metropolis Healthcare Ltd
Investor Relations

Metropolis Healthcare Ltd., a pioneer in the diagnostics industry, embarked on its journey in 1980 under the visionary leadership of Dr. Sushil Kanubhai Shah. This Mumbai-based company quickly established itself as a trusted name, offering a comprehensive range of diagnostic services, including pathology tests, radiology, and wellness solutions. The heart of its operations lies in its expansive network of laboratories and collection centers strategically distributed across India and several international locations. By leveraging state-of-the-art technology and maintaining rigorous quality standards, Metropolis has positioned itself as a forerunner in providing precise and reliable medical test results. This was especially crucial as the demand for accurate healthcare diagnostics surged, driven by an increasingly health-conscious population.

Metropolis generates its revenue primarily through fees charged for its broad spectrum of diagnostic tests that cater to a variety of health needs, from routine screenings to specialized, high-complexity tests. Its business model capitalizes on partnerships with healthcare providers, hospitals, and corporations, offering customized health packages and diagnostic solutions that ensure a steady flow of clientele. By integrating advanced testing technologies and continuously expanding its service portfolio, the company taps into diverse revenue streams, which include corporate wellness programs and home health services. This diversified approach not only enhances its financial stability but also solidifies its reputation as a go-to healthcare partner for individuals, corporate clients, and healthcare institutions alike.

Show more
Loading
METROPOLIS
BSE Sensex 30
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Last Earnings Call
Fiscal Period
Q2 2026
Call Date
Nov 6, 2025
AI Summary
Q2 2026

Strong Revenue Growth: Metropolis delivered 23% year-over-year revenue growth for Q2 and H1 FY '26, with organic revenue up 12% for the quarter.

Margin Expansion: Organic EBITDA margin improved to 26.8% (up 60 bps YoY), while group margin stood at 25.4%. Core Diagnostics margins moved to high-single digits.

Guidance Maintained: Management reaffirmed full-year guidance for organic margin expansion of 70–100 bps and double-digit volume growth, with no planned price hikes for the remainder of the year.

Acquisition Integration: Recent acquisitions contributed 11% to revenue growth; integration and clean-up remain on track, with year 1 focused on synergy realization and efficiency.

Operational Efficiency & AI: Continued investment in automation, AI, and digitization to drive productivity, streamline operations, and enhance customer experience.

TruHealth & Specialty: TruHealth and Specialty segments saw robust organic growth of 21% and 15% respectively, aided by new offerings and targeted marketing.

Stable Competitive Landscape: No major new entrants; consolidation continues to favor organized players like Metropolis.

Clinical Trial Upside: Clinical trial business contributed positively in Q2, with margins better than company average, though it remains a small part of overall revenue.

Key Financials
EBITDA (Organic)
INR 104.8 crores
EBITDA Margin (Organic)
26.8%
EBITDA Margin (Group)
25.4%
PAT (Organic)
INR 53 crores
PAT Margin (Organic)
13.6%
PAT (Group)
INR 52.9 crores
PAT Margin (Group)
12.3%
Patient Volume (Organic)
3.6 million
Test Volume (Organic)
7.4 million
Patient Volume (Group)
3.7 million
Test Volume (Group)
7.9 million
B2C Revenue (Organic)
INR 230 crores
Contribution from B2C (Organic)
59%
Contribution from B2C (Group)
56%
Other Earnings Calls

Management

Ms. Ameera Sushil Shah
Executive Chairperson
No Bio Available
Dr. Sushil Kanubhai Shah
Founder & Chairman Emeritus
No Bio Available
Mr. Surendran Chemmenkotil
Chief Executive Officer
No Bio Available
Mr. Aditya Shinde
Interim Chief Financial Officer
No Bio Available
Mr. Kannan Alangadan
Chief Operating Officer
No Bio Available
Dr. Kirti Chadha
Chief Scientific & Innovation Officer
No Bio Available
Mr. Pinakin Shah
Chief Information Officer
No Bio Available
Mr. Kamlesh Kulkarni
Head of Legal & Secretarial and Compliance Officer
No Bio Available
Mr. Jeyasingh Balakrishnan
Head of Public Relations & Corporate Communications
No Bio Available
Mr. Mohan Menon
Chief Marketing Officer
No Bio Available

Contacts

Address
HARYANA
Gurgaon
Nh-8, Sco No. 30, Sector 15, Part Ii
Contacts